Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Gilead Sciences is acquiring a liver disease drug development program from the privately held German company Phenex Pharmaceuticals. Gilead will pay up to $470 million for Phenex’s small-molecule farnesoid X receptor (FXR) agonists. FXR is a nuclear hormone receptor that regulates bile acid, lipid, and glucose homeostasis, which can help reduce liver steatosis and inflammation and may help prevent liver fibrosis.
This article has been sent to the following recipient: